03.18.24 -- Small Org With Big Global Impact

Cell & Gene: The Podcast talks to Life Biosciences' CSO, Sharon Rosenzweig-Lipson, Ph.D., about the Boston-based biotech's cellular rejuvenation therapies for the treatment of age-related diseases. The episode also dives into the company’s lead program, the gene therapy OSK, that is being advanced in two optic neuropathies – glaucoma and a rare eye disease of aging called NAION. Listen now!

The revisions to EU Annex 1 set the stage for the future direction of the pharma/biotech industry. Explore key takeaways and interesting changes for risk management and contamination control strategies.

Industry experts discuss the concept of a trial platform as a service and how it can accelerate and enhance the day-to-day functions of clinical operations throughout the entire life cycle of a study.

In the era of seamless development, reducing time to clinic and getting rapid approval is key. An integrated approach can accelerate timelines, avoid communication pitfalls, and improve outcomes.

Market demand for bispecific antibody-based therapies (BsAbs) is growing rapidly due to the wide range of applications for these molecules in research and diagnostics.

Review the efficacy of fast stable pools in generating purified product at an early stage and learn how to accelerate the journey toward first-in-human trials and proof-of-concept studies.

Learn more about the potential of allogeneic cell therapies to combine the efficacy of personalized medicine with the scalability, accessibility, and uniformity of traditional off-the-shelf therapeutics.